[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:breast-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":309,"states":397},"Breast Carcinoma",1067,904,[8,16,23,30,37,43,49,55,61,67,73,79,85,91,98,104,109,115,121,127,133,139,145,151,157,162,168,173,178,184,190,196,202,208,214,220,226,232,238,244,250,256,262,268,274,280,286,292,298,303],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06998407","ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and\u002For Endocrine Therapy in Advanced Solid Tumors",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:49.658025Z","2026-07-30T01:46:14.469288Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06369285","A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer",[20],"Phase 2","2026-08-26T02:15:44.309045Z","2026-07-30T01:46:14.465636Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07205822","A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer",[27],"Phase 3","2026-08-26T02:16:16.169331Z","2026-07-30T01:46:14.435695Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT07257484","Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors",[34],"Phase 4","2026-08-26T02:17:48.768272Z","2026-07-24T01:27:14.894137Z",{"nct_id":38,"title":39,"phases":40,"status":13,"updated_at":41,"content_modified":42},"NCT06234098","Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors",[12],"2026-08-26T02:18:29.369233Z","2026-07-24T01:27:14.872455Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT06444269","Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial",[20],"2026-08-26T02:17:16.980188Z","2026-07-19T19:36:05.129390Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT05592938","Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)",[],"2026-08-26T02:16:34.792807Z","2026-07-19T19:36:05.117763Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT04230109","Sacituzumab Govitecan In TNBC",[20],"2026-08-26T02:15:00.557154Z","2026-07-19T19:36:05.114205Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT05846789","SOC Chemotherapy +\u002F- Tocilizumab for Triple Negative and ER-low Breast Cancers",[20],"2026-08-26T02:18:45.196599Z","2026-07-05T05:32:16.815779Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05812807","Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab",[27],"2026-08-26T02:18:51.833592Z","2026-07-05T05:32:16.814326Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05696626","Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+\u002FHER2- Breast Cancer With an ESR1 Mutation",[27],"2026-08-26T02:18:17.950264Z","2026-07-05T05:32:16.810317Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT05716893","Study of Aerobic Training for People Receiving Treatment for Breast Cancer",[20],"2026-08-26T02:17:21.315591Z","2026-07-05T05:32:16.809788Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT04523857","ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer",[20],"2026-08-26T02:16:20.336282Z","2026-07-05T05:32:16.775076Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":96,"content_modified":97},"NCT06678269","A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer",[95],"Phase 1","2026-08-26T02:17:51.502023Z","2026-07-05T05:32:16.767726Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT06638307","A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer",[95],"2026-08-26T02:19:16.454910Z","2026-07-05T05:32:16.765634Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":77,"content_modified":108},"NCT07158021","Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial",[20],"2026-07-05T05:32:16.735289Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT07120100","Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors",[],"2026-08-26T02:18:04.640417Z","2026-07-05T05:32:16.734955Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT07102381","A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer",[20],"2026-08-26T02:18:23.582895Z","2026-07-05T05:32:16.733599Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06953882","Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy",[20],"2026-08-26T02:18:19.586423Z","2026-07-05T05:32:16.722347Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT06923527","Circulating Tumor DNA",[20],"2026-08-26T02:15:26.669629Z","2026-07-05T05:32:16.704259Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT06917313","FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy",[20],"2026-08-26T02:17:19.710918Z","2026-07-05T05:32:16.702580Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT06827236","A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer",[12],"2026-08-26T02:18:27.904411Z","2026-07-05T05:32:16.696434Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT06797635","Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive\u002FHER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)",[20],"2026-08-26T02:18:34.622081Z","2026-07-05T05:32:16.694743Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT06757634","Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)",[27],"2026-08-26T02:15:54.846520Z","2026-07-05T05:32:16.692648Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":119,"content_modified":161},"NCT07222215","PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)",[20],"2026-07-05T05:32:16.667982Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT07198724","ERADICATE: A Phase Ib\u002FII Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4\u002F6 Inhibitor and Endocrine-resistant HR+\u002FHER2-low or HER2-ultralow Metastatic Breast Cancer",[12],"2026-08-26T02:18:00.873391Z","2026-07-05T05:32:16.660998Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":125,"content_modified":172},"NCT07407920","Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial",[20],"2026-07-05T03:45:20.251405Z",{"nct_id":174,"title":175,"phases":176,"status":13,"updated_at":131,"content_modified":177},"NCT03424005","A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer",[12],"2026-06-17T19:21:16.689089Z",{"nct_id":179,"title":180,"phases":181,"status":13,"updated_at":182,"content_modified":183},"NCT07604571","Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+\u002FHER2- Breast Cancer",[95],"2026-08-26T02:18:53.782384Z","2026-06-06T00:48:49.527214Z",{"nct_id":185,"title":186,"phases":187,"status":13,"updated_at":188,"content_modified":189},"NCT07391774","Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial",[27],"2026-08-26T02:16:15.345907Z","2026-06-06T00:48:49.526313Z",{"nct_id":191,"title":192,"phases":193,"status":13,"updated_at":194,"content_modified":195},"NCT07492641","BGB-43395 Plus Letrozole Versus CDK4\u002F6i Plus Letrozole for Patients With Advanced or Metastatic HR+\u002FHER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease",[27],"2026-08-26T02:16:08.402952Z","2026-06-04T01:30:07.901883Z",{"nct_id":197,"title":198,"phases":199,"status":13,"updated_at":200,"content_modified":201},"NCT07612215","Elacestrant in Advanced Triple Positive Breast Cancer",[12],"2026-08-26T02:17:07.954622Z","2026-05-29T15:36:40.230950Z",{"nct_id":203,"title":204,"phases":205,"status":13,"updated_at":206,"content_modified":207},"NCT05309655","Cardiac Outcomes With Near-Complete Estrogen Deprivation",[],"2026-08-03T03:07:45.344605Z","2026-05-29T15:36:40.173172Z",{"nct_id":209,"title":210,"phases":211,"status":13,"updated_at":212,"content_modified":213},"NCT07558733","Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+\u002FHER2- Advanced\u002FMetastatic Breast Cancer",[12],"2026-08-26T02:17:45.190188Z","2026-05-13T02:55:06.724801Z",{"nct_id":215,"title":216,"phases":217,"status":13,"updated_at":143,"content_modified":219},"NCT07319195","Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)",[218],"Early Phase 1","2026-05-13T02:55:06.687296Z",{"nct_id":221,"title":222,"phases":223,"status":13,"updated_at":224,"content_modified":225},"NCT07220135","Trial of Neoadjuvant THP vs TCHP for HER2-Amplified\u002FPositive Breast Cancer",[20],"2026-08-26T02:16:03.788292Z","2026-05-13T02:55:06.675627Z",{"nct_id":227,"title":228,"phases":229,"status":13,"updated_at":230,"content_modified":231},"NCT05898399","Study of ART6043 in Advanced\u002FMetastatic Solid Tumors Patients (POLKA)",[12],"2026-08-26T02:17:32.059863Z","2026-05-13T02:55:06.392298Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT05595499","Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors",[20],"2026-08-26T02:16:54.044282Z","2026-05-05T02:47:14.270893Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":242,"content_modified":243},"NCT05455619","Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+\u002FHer2- Breast Cancer",[12],"2026-08-26T02:16:28.221034Z","2026-05-05T02:47:14.270026Z",{"nct_id":245,"title":246,"phases":247,"status":13,"updated_at":248,"content_modified":249},"NCT07311993","Phase 1 Study of CLR 125 in Triple Negative Breast Cancer",[95],"2026-08-26T02:17:05.997056Z","2026-05-05T02:43:29.732695Z",{"nct_id":251,"title":252,"phases":253,"status":13,"updated_at":254,"content_modified":255},"NCT03011684","Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial",[27],"2026-08-26T02:15:34.659160Z","2026-05-05T02:43:29.731643Z",{"nct_id":257,"title":258,"phases":259,"status":13,"updated_at":260,"content_modified":261},"NCT03351348","Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control",[27],"2026-08-03T03:23:28.660374Z","2026-05-05T02:43:29.731633Z",{"nct_id":263,"title":264,"phases":265,"status":13,"updated_at":266,"content_modified":267},"NCT03449238","Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients",[12],"2026-08-26T02:17:36.611194Z","2026-05-05T02:43:29.730452Z",{"nct_id":269,"title":270,"phases":271,"status":13,"updated_at":272,"content_modified":273},"NCT06507618","Pre-Operative Window of ET to Inform RT Decisions (POWER II)",[27],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:29.726692Z",{"nct_id":275,"title":276,"phases":277,"status":13,"updated_at":278,"content_modified":279},"NCT06042569","Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial",[20],"2026-08-26T02:19:29.922117Z","2026-05-05T02:43:29.722865Z",{"nct_id":281,"title":282,"phases":283,"status":13,"updated_at":284,"content_modified":285},"NCT06099769","A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer",[20],"2026-08-26T02:17:47.813245Z","2026-05-05T02:43:29.707998Z",{"nct_id":287,"title":288,"phases":289,"status":13,"updated_at":290,"content_modified":291},"NCT03990896","Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial",[20],"2026-08-26T02:16:57.705506Z","2026-05-05T02:43:29.705241Z",{"nct_id":293,"title":294,"phases":295,"status":13,"updated_at":296,"content_modified":297},"NCT06185205","ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy",[20],"2026-08-26T02:17:02.694423Z","2026-05-05T02:43:29.681174Z",{"nct_id":299,"title":300,"phases":301,"status":13,"updated_at":212,"content_modified":302},"NCT04965064","Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling",[20],"2026-05-05T02:43:29.668617Z",{"nct_id":304,"title":305,"phases":306,"status":13,"updated_at":307,"content_modified":308},"NCT05508906","Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer",[95],"2026-08-26T02:15:33.331531Z","2026-05-05T02:43:29.666612Z",[310,314,318,322,326,330,334,338,342,346,349,353,356,360,364,367,371,374,377,380,383,387,390,393],{"biomarker":311,"count":312,"slug":313},"ERBB2 Gene",73,"erbb2-gene",{"biomarker":315,"count":316,"slug":317},"ESR1 Gene",37,"esr1-gene",{"biomarker":319,"count":320,"slug":321},"HR LYSINE DEMETHYLASE AND NUCLEAR RECEPTOR COREPRESSOR",36,"hr-lysine-demethylase-and-nuclear-receptor-corepressor",{"biomarker":323,"count":324,"slug":325},"BRCA1 Gene",23,"brca1-gene",{"biomarker":327,"count":328,"slug":329},"BRCA2 Gene",22,"brca2-gene",{"biomarker":331,"count":332,"slug":333},"PIK3CA Gene",21,"pik3ca-gene",{"biomarker":335,"count":336,"slug":337},"PGR Gene",17,"pgr-gene",{"biomarker":339,"count":340,"slug":341},"Partner and Localizer of BRCA2",16,"partner-and-localizer-of-brca2",{"biomarker":343,"count":344,"slug":345},"PTEN Gene",13,"pten-gene",{"biomarker":347,"count":344,"slug":348},"TP53 Gene","tp53-gene",{"biomarker":350,"count":351,"slug":352},"MKI67 Gene",10,"mki67-gene",{"biomarker":354,"count":351,"slug":355},"Programmed Cell Death 1 Ligand 1","programmed-cell-death-1-ligand-1",{"biomarker":357,"count":358,"slug":359},"MSI1 Gene",9,"msi1-gene",{"biomarker":361,"count":362,"slug":363},"RAD51C Gene",8,"rad51c-gene",{"biomarker":365,"count":362,"slug":366},"RAD51D Gene","rad51d-gene",{"biomarker":368,"count":369,"slug":370},"BRCA Gene Family",7,"brca-gene-family",{"biomarker":372,"count":369,"slug":373},"CDH1 Gene","cdh1-gene",{"biomarker":375,"count":369,"slug":376},"G1\u002FS-Specific Cyclin-E1","g1-s-specific-cyclin-e1",{"biomarker":378,"count":369,"slug":379},"MRC1 wt Allele","mrc1-wt-allele",{"biomarker":381,"count":369,"slug":382},"Serine\u002FThreonine-Protein Kinase Chk2","serine-threonine-protein-kinase-chk2",{"biomarker":384,"count":385,"slug":386},"BARD1 Gene",6,"bard1-gene",{"biomarker":388,"count":385,"slug":389},"Prolyl Endopeptidase FAP","prolyl-endopeptidase-fap",{"biomarker":391,"count":385,"slug":392},"RAC-Alpha Serine\u002FThreonine Kinase","rac-alpha-serine-threonine-kinase",{"biomarker":394,"count":395,"slug":396},"ATM Gene",5,"atm-gene",[398,402,406,410,414,418,422,425,429,433,437,441,445,449,453,457,461,464,468,472,476,480,484,488],{"state":399,"count":400,"slug":401},"Texas",315,"texas",{"state":403,"count":404,"slug":405},"California",292,"california",{"state":407,"count":408,"slug":409},"New York",277,"new-york",{"state":411,"count":412,"slug":413},"Florida",248,"florida",{"state":415,"count":416,"slug":417},"Massachusetts",191,"massachusetts",{"state":419,"count":420,"slug":421},"North Carolina",157,"north-carolina",{"state":423,"count":420,"slug":424},"Pennsylvania","pennsylvania",{"state":426,"count":427,"slug":428},"Tennessee",156,"tennessee",{"state":430,"count":431,"slug":432},"Virginia",150,"virginia",{"state":434,"count":435,"slug":436},"New Jersey",148,"new-jersey",{"state":438,"count":439,"slug":440},"Ohio",146,"ohio",{"state":442,"count":443,"slug":444},"Illinois",139,"illinois",{"state":446,"count":447,"slug":448},"Michigan",132,"michigan",{"state":450,"count":451,"slug":452},"Missouri",125,"missouri",{"state":454,"count":455,"slug":456},"Washington",111,"washington",{"state":458,"count":459,"slug":460},"Maryland",108,"maryland",{"state":462,"count":459,"slug":463},"Minnesota","minnesota",{"state":465,"count":466,"slug":467},"Arizona",107,"arizona",{"state":469,"count":470,"slug":471},"Colorado",105,"colorado",{"state":473,"count":474,"slug":475},"Connecticut",91,"connecticut",{"state":477,"count":478,"slug":479},"Wisconsin",88,"wisconsin",{"state":481,"count":482,"slug":483},"Georgia",84,"georgia",{"state":485,"count":486,"slug":487},"Utah",72,"utah",{"state":489,"count":490,"slug":491},"Oregon",71,"oregon"]